Form 4: Edesa Biotech CEO Pardeep Nijhawan Receives Restricted Share Units

Edesa Biotech CEO Pardeep Nijhawan reports the acquisition of 3,317 common shares through restricted share units, increasing his direct and indirect beneficial ownership.

Summary

• Pardeep Nijhawan, CEO of Edesa Biotech, Inc., filed a Form 4 on August 2, 2024, reporting a transaction that occurred on August 1, 2024.
• Nijhawan acquired 3,317 common shares through a grant of restricted share units, which vested fully upon grant, under the company's 2019 Equity Incentive Compensation Plan.
• The acquisition was priced at $0.
• Following the transaction, Nijhawan directly owns 126,263 common shares.
• Nijhawan also indirectly owns shares through several entities, including Pardeep Nijhawan Medicine Professional Corporation (341,702 shares), The New Nijhawan Family Trust 2015 (32,609 shares), The Digestive Health Clinic Inc. (32,013 shares), and 1968160 Ontario Inc. (53,104 shares).

Sentiment

Score: 6

Explanation: The document is a neutral report of a standard executive compensation practice. It doesn't contain overtly positive or negative information.

Positives

• The grant of restricted share units to the CEO aligns his interests with those of the shareholders.
• The vesting of the shares upon grant suggests immediate alignment and motivation.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The grant of restricted share units could positively impact shareholders by aligning management's interests with the company's performance.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Edesa Biotech, Pardeep Nijhawan, Form 4, restricted share units, beneficial ownership, EDSA, CEO, equity incentive plan